title: Is there any association between TACSTD2, KIAA1253, Ku70 and mutant KRAS gene expression and clinical-pathological features of colorectal cancer?
abstract: OBJECTIVE
  To determine the quantitative gene expression of KRAS codon 12 mutant, TACSTD2, Ku70 and SERIN1 in samples of tumor tissue and to relate them with clinical-pathological characteristics of colorectal cancer.
  
  
  METHODS
  Samples of tumor and normal tissue of patients surgically treated for colorectal cancer between July 2005 and July 2009 were stored in a tissue bank. These samples were studied with the technique of real-time polymerase chain reaction in respect to expression of the following genes: KRAS codon 12 mutation, TACSTD2, Ku70, and SERIN1.
  
  
  RESULTS
  Tumor samples of 37 patients were studied. The mean age was 65.5 years. Twenty one patients (56.8%) were male. Nine patients (24.3%) were classified as TNM stage I, 11 patients (29.8%) as TNM stage II, eight patients (21.6%) as TNM stage III and nine patients (24.3%) as TNM stage IV. The Ku70 expression in poorly-differentiated tumors is significantly higher than in well and moderately-differentiated tumors (2.76 vs. 1.13; p < 0.05). SERIN1, TACSTD2 and KRAS codon 12 mutation are not associated with clinical-pathological characteristics of colorectal cancer.
  
  
  CONCLUSIONS
  Ku70 expression in poorly-differentiated tumors is significantly higher than in well and moderately-differentiated colorectal tumors.
authors.affiliation: Postgraduate Program in Medicine: Surgical Sciences, Federal University of Rio Grande do Sul, Ramiro Barcelos Street 2400 , Porto Alegre, RS, 90035-003, Brazil. tiago.lealghezzi@ieo.it
authors.forename: T L
authors.initials: TL
authors.lastname: Ghezzi
authors.forename: I S
authors.initials: IS
authors.lastname: Brum
authors.forename: V
authors.initials: V
authors.lastname: Biolchi
authors.forename: B
authors.initials: B
authors.lastname: Garicochea
authors.forename: L S
authors.initials: LS
authors.lastname: Fillmann
authors.forename: O C
authors.initials: OC
authors.lastname: Corleta
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism; D034961:Antigens, Nuclear / Q000235:genetics / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000235:genetics / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000235:genetics / Q000473:pathology*; D003430:Cross-Sectional Studies; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D000072200:Ku Autoantigen; D008297:Male; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D000951:Antigens, Neoplasm; D034961:Antigens, Nuclear; D015815:Cell Adhesion Molecules; D004268:DNA-Binding Proteins; C117307:KRAS protein, human; D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; C477932:SERINC1 protein, human; C499380:TACSTD2 protein, human; C000606509:Xrcc6 protein, human; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000072200:Ku Autoantigen